Lyndsay Willmott

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 406 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture

Valerie Trapp, Basmina Parmakhtiar, Vartan Papazian et al. · Angiogenesis · 2010 · 115 citations · Full text

Medicine, Cancer Biology, Oncology +16

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

M.A. Powell, Line Bjørge, Lyndsay Willmott et al. · Annals of Oncology · 2024 · 102 citations · Full text

Medicine, Gynecology, Oncology +15

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer

Alessandro D. Santin, Bradley R. Corr, Alexander I. Spira et al. · Journal of Clinical Oncology · 2024 · 57 citations · Full text

Medicine, Oncology, Pharmacology +14

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Annals of Oncology · 2020 · 36 citations

Medicine, Gynecology, Oncology +10